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A B S T R A C T
The European Union’s ban on animal testing for cosmetic ingredients and products has generated a strong
momentum for the development of in silico and in vitro alternative methods. One of the focus of the
COSMOS project was ab initio prediction of kinetics and toxic effects through multiscale pharmacokinetic
modeling and in vitro data integration. In our experience, mathematical or computer modeling and in
vitro experiments are complementary. We present here a summary of the main models and results
obtained within the framework of the project on these topics. A ﬁrst section presents our work at the
organelle and cellular level. We then go toward modeling cell levels effects (monitored continuously),
multiscale physiologically based pharmacokinetic and effect models, and route to route extrapolation.
We follow with a short presentation of the automated KNIME workﬂows developed for dissemination
and easy use of the models. We end with a discussion of two challenges to the ﬁeld: our limited ability to
deal with massive data and complex computations.
ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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journa l homepage : www.e l sev ier .com/ loca te / toxicol1. Introduction
The European decision to ban animal testing for cosmetic
ingredients has generated a strong momentum for the develop-
ment of in silico and in vitro alternative methods. One of the aims of
the COSMOS project (funded by the European Commission and by
Cosmetics Europe under the 7th Framework Programme) was to
develop approaches for the ab initio prediction of kinetics and toxic
effects through multiscale pharmacokinetic modeling and in vitro
data integration. We present here a summary of the relevant
models and results obtained by the COSMOS team. Our major
activities were focused on modeling toxicokinetics and toxicody-
namics (effects) in vitro and in vivo, which are required to perform
quantitative in vitro to in vivo extrapolation (QIVIVE) (Adler et al.,
2011; Bessems et al., 2014; Coecke et al., 2012; Quignot et al., 2014).
Kinetic modeling is a relatively well developed ﬁeld, with well
established compartmental or physiologically based* Corresponding author.
E-mail address: frederic.bois@ineris.fr (F.Y. Bois).
http://dx.doi.org/10.1016/j.tox.2016.05.026
0300-483X/ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
nd/4.0/).
Please cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026pharmacokinetic (PBPK) models (Corley, 2010; Gibaldi and Perrier,
1982; Peters, 2011). In PBPK models, the transport and overall fate
of the substance administered is governed by anatomic and
physiological considerations. The models can have a generic
structure, which makes them easier to use (no need to develop
new equations for a new substance) (Beaudouin et al., 2010; Corley,
2010; Jamei et al., 2009; Willmann et al., 2007). Most of their
parameters are physiological, meaning that they do not depend on
the chemical considered, but solely on the subject exposed (at least
when exposure to the chemical does not alter appreciably the body
functions, such as blood ﬂows). Compilations of average parameter
values for several species are available, and even values for speciﬁc
sub-groups (children, pregnant women, elderly people . . . ) (Bois
et al., 2010). The few remaining parameters, which depend on
chemical structure, are sufﬁciently mechanistic to be obtained by
quantitative structure-property relationships (QSPR), or in vitro
experiments (Hamon et al., 2015). In vitro kinetic models are
different from PBPK models, in that they are not particularly
physiological, but rather represent the in vitro system modeled.
Some generic models have been proposed for simple in vitro
systems – including by us, the virtual cell based assay (VCBA)article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
roaches for assessing cosmetic ingredients safety, Toxicology (2016),
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compartmental systems, micro-chips) require speciﬁc develop-
ments (Armitage et al., 2014; Crean et al., 2014; Ouattara et al.,
2011; Truisi et al., 2015; Wilmes et al., 2013; Zaldívar et al., 2010).
The state of the art is far less advanced for “extrapolatable”
toxicodynamic models. Traditional toxicodynamic models are
similar to compartmental models (and in fact extend those with ad
hoc “effect” compartments). They are data ﬁtted and thus speciﬁc
for a given experiment or clinical trial (Csajka and Verotta, 2006);
they are not designed for extrapolations (except very basic time
and dose extrapolations). The equivalent of PBPK models in
toxicodynamics are biologically-based models. Among the earliest
of such models were the biologically based carcinogenesis models
(Armitage, 1985; Moolgavkar and Knudson, 1981). However, given
the obscurity and complexity of the cancer process (still not
elucidated), those models were at the same time too simple (to
avoid criticisms) and too complex (to be used in a regulatory
framework). They were never really used for risk assessment,
except in the extremely simpliﬁed form of the multistage cancer
dose-response model (Crump and Howe, 1984). A new generation
of models is emerging with “systems biology” models (Geenen
et al., 2012; Jusko, 2013) and “physiome” (or virtual human)
models (Bassingthwaighte, 2000; Hunter and Borg, 2003). Systems
biology models are bottom-up models rooted in biochemistry and
beneﬁting from our increasing understanding of cellular signaling
and transcriptional control pathways (facilitated by the explosion
of omics data). Physiome models are inherently top-down and
multiscale and therefore the closest equivalent to PBPK models
(PBPK models can in fact be thought of as vascular body-level
solute transport models). They started as high-level descriptions of
organ physiology and are increasing their resolution to the cell
level (arguably the right level to start understanding the origin of
most toxic injuries). Originating from two different research
communities (biochemists vs. physiologists) these two approaches
are slowly merging as they meet each other at the tissue level.
Furthermore, the two approaches did not escape the attention of
the members of the 21st century toxicology panel of the US
National Academy of Sciences, who placed them at the heart of
their vision statement (National Research Council (NRC), 2007),
gaining much attention, given the authority of its authors. The
ensuing consideration of toxicity pathways and modes of action
(MOA) met happily the adverse outcome pathway (AOP) thinking
in vogue in the ecotoxicology community (Tollefsen et al., 2014),
and is still hesitating about changing name . . . Meanwhile, virtual
organ programs have been heavily funded (e.g., by the Virtual Liver
project of the German Ministry of Research) (Holzhütter et al.,
2012) given their potential impact for predictive drug safety
assessment. In short, we are witnessing a convergence of systems
biology and virtual organs modeling around the concept of
quantitative MOAs, fully amenable to QIVIVE and risk assessment.
This paper follows a bottom-up integration logic: A ﬁrst section
presents our work at the organelle/cellular level. We then go
toward modeling cell levels effects (monitored continuously),
multiscale PBPK and effect models, and route to route extrapola-
tion. We end with a short presentation of the automated KNIME
workﬂows developed for dissemination and easy use of our
models.
2. From organelles to cells
Before manifesting themselves at the cellular level, most
toxicity effects start at the scale of organelles. Mitochondria in
particular are often targets of toxicity. They perform two critical
functions in the cell: the production of more than 90% of the cell’s
energy, and the control of cell survival as an integral part of
programmed cell death (apoptosis). Three general adverse effectsPlease cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026result from mitochondrial toxicity: 1. Disrupted energy metabo-
lism; 2. Increased free radical generation; and 3. Altered apoptosis.
We addressed the disruption of mitochondrial energy metabolism
by measuring and simulating mitochondrial membrane potential
(MMP). The measurement of MMP provides information on the
mitochondrion's ability to carry out oxidative phosphorylation
(which couples electron transfer to ATP synthesis), and transfer
ions and substrates across its inner membranes (Nicholls and
Ward, 2000). Thus, one of the most common methods to detect
mitochondrial toxicity is the monitoring of the cells' MMP. A
variety of ﬂuorescent dyes can be used to that effect in high
throughput screening. For example, cationic dyes distribute to the
mitochondrial matrix in accordance with Nernst's equation
(Mitchell and Moyle, 1969), so that the MMP is given by:
MMP ¼ a  Vð ÞR  T
F
log
Ccyt
Cmit
 
ð1Þ
where R is the gas constant, T the temperature, F the Faraday
constant, Ccyt the concentration of the chemical in the cell cytosol,
Cmit its concentration in mitochondria, a a proportionality
constant, and V the cell viability. Cmit is computed by integration
of the following differential equation:
@Cmit
@t
¼ Kmit Caq  Cmit
  ð2Þ
where Caq is the concentration in the aqueous phase of the cell, and
Kmit is a diffusion rate constant dependent on the chemical and cell
line used.
We report here results on the in vitro MMP disruption of
HepaRG cells by caffeine, carbonyl cyanide-p-triﬂuoromethoxy-
phenylhydrazone (FCCP), amiodarone and estragole. The MMP was
measured and modeled using an extension of the VCBA model
(Zaldívar et al., 2011, 2010). That model, like some others (Armitage
et al., 2014; Crean et al., 2014; Hamon et al., 2014; Pomponio et al.,
2014; Truisi et al., 2015; Wilmes et al., 2013) takes into account the
fate of the test compound in vitro: partitioning between plastic vial
walls, headspace, serum proteins and cells. It includes a model of
cell growth and death and has been linked to a threshold model for
cell killing. In the course of the COSMOS project, we developed
VCBA models for amiodarone, caffeine, FCCP, coumarin, estragole,
ethanol, and nicotine. To simulate MMP data, a mitochondrial sub
cellular compartment and Nernst’s equation were added to the
VCBA model. In vitro HepaRG MMP data were used to optimize two
parameters of Nernst's equation (a and Kmit) by least-square
minimization. Fig. 1 shows the measured and simulated MMP as a
function of the exposure concentration of the four chemicals
assayed. The model was able to correctly reproduce the
amiodarone and estragole data. The caffeine data show a peak
at 0.01 M, which could not be reproduced by the model. The FCCP
induced fast decrease of MMP at concentrations lower than 0.1 mM
was not well captured by the model either. More experiments with
different chemicals will be needed to fully understand the
determinants of prediction accuracy.
3. Modeling in vitro kinetics and continuously measured cell
effects
Two complementary models were used to analyze toxic effects
in vitro, at the cell level. The ﬁrst model is the VCBA model
introduced above (Zaldívar et al., 2011, 2010). This model is well
suited to analyze ﬁxed point cytotoxicity data (as in high-content
imaging assays). The second model can be used for continuous
cytotoxicity monitoring, using electrical impedance measure-
ments (Xing et al., 2006).
The latter model describes HepaRG cell viability loss following
exposure to hepatotoxic molecules. It was applied it to threeroaches for assessing cosmetic ingredients safety, Toxicology (2016),
Fig. 1. Observed (black dots) and VCBA model simulated values (red circles and
lines) of mitochondrial membrane potential in HepaRG cells exposed in vitro to four
test compounds; carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP),
caffeine, amiodarone, and estragole. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Normalized Cell Index (NCI) of HepaRG cells exposed once to coumarin at
various concentrations. The data and the model predictions are represented by
points and lines, respectively (adapted from Teng et al., 2015).
Fig. 3. Normalized Cell Index (NCI) of HepaRG cells exposed every 2–3 days to
coumarin at various concentrations for 4 weeks. The data and the model predictions
are represented by points and lines, respectively.
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phenone-2. Our model couples dynamic descriptions of the major
in vitro kinetic processes involved with a simple model of viability
loss (see Teng et al., 2015 for details).
The data were obtained using HepaRG cells (Guillouzo et al.,
2007), exposed to the selected chemicals either once (at
concentrations ranging from 0.008 to 8 mM with a 48 h follow-
up) or during repeated exposures (at concentrations ranging from
0.128 to 8 mM, with a follow-up of 4 weeks). Cellular viability was
monitored by impedance measurements with an in vitro label-free
cell-based monitoring system (xCELLigenceTM, ACEA Biosciences,
Roche Diagnostics). The impedance of HepaRG cells was converted
to a normalized cell index (NCI). A decrease in NCI is indicative of
cell detachment or death (Xing et al., 2006).
We modeled the in vitro dynamic decrease in concentration for
the substance of interest by an apparent linear process (lumping
unspeciﬁc physico-chemical reactions, plastic binding, evapora-
tion and linear metabolism) or by a Michaelis-Menten equation
when saturable cellular metabolism was observed.
For coumarin and isoeugenol, the time-course of cell viability
was modeled using Eq. (5), parameterized by a killing rate (b) and a
no effect concentration, NEC.
dN
dt
¼ b Ci  NECð ÞN; if Ci > NEC;
0 otherwise

ð5Þ
N being the number of cells in the well. For benzophenone-2, we
used a slightly more complex model to describe cell spreading at
sub-toxic concentrations (Teng et al., 2015). The model parameters
were estimated by least square ﬁtting of the model to the
impedance data.
On the basis of goodness of ﬁt, linear loss was used for
coumarin. Saturable loss gave better ﬁts for isoeugenol and
benzophenone-2. As shown for coumarin in Fig. 2 (for short-
exposures) and in Fig. 3 (for repeated exposures), our model
described rather well the kinetics of real-time impedancePlease cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026measurements in HepaRG cells at various exposure doses. Similar
results were obtained for isoeugenol and benzophenone-2 (Teng
et al., 2015).
However for isoeugenol and benzophenone-2, the acute models
failed to predict long-term exposures and vice-versa. This could be
due to various phenomena not accounted for by the model, such at
the reversibility of plastic binding, or the complex dynamics of
cellular response and adaptation to stress. We have actually
observed that in vitro repeated exposures experiments tend to lead
to complex time-dose-response relationship much more difﬁcult
to interpret and analyse than acute toxicity data (Hamon et al.,
2014; Wilmes et al., 2013). This should not be taken as a problem to
avoid, but as a challenge to resolve, because such complex
responses are probably more representative of the in vivo cellular
responses. In any case, while awaiting better models and deeper
understanding, it is recommended to use the proper experimental
data to predict the corresponding effect.roaches for assessing cosmetic ingredients safety, Toxicology (2016),
Fig. 4. Comparison of HepaRG cell viability exposed to coumarin at 24 h, as
measured by Cellomics and estimated by the VCBA model (black dots) or impedance
measurements and Teng’s model (red dots). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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model estimates of HepaRG cells viability after exposure to various
concentrations of coumarin. The VCBA model used static Cellomics
assay data to assess cell viability. Cell-level toxicodynamics were
described by two parameters: a no-effect concentration and a
killing rate. Compared to Cellomics, impedance metrics provide
slightly higher values of cell viability. However, the two tests give
comparable results when experimental variability is taken into
account.
4. From in vitro to in vivo with multiscale PBPK models
4.1. In silico predictions of PBPK model parameters
Quantitative structure activity/property relationships (QSARs/
QSPRs) are theoretical (in silico) models that relate the structure of
chemicals to their biologic activities or properties (e.g., physico-
chemical, partitioning or fate property). QSAR models can be used
to parameterize PBPK models by providing predictions for basic
physico-chemical properties (e.g., ionization constant, octanol over
water partition coefﬁcient, distribution coefﬁcient or aqueous
solubility) as well as key ADME properties (e.g., extent of
gastrointestinal absorption, oral bioavailability, plasma protein
binding, metabolism rate by cytochromes or clearance). A number
of QSAR models and software tools are available for the prediction
of ADME related properties (Mostrag-Szlichtyng and Worth, 2010;
Worth et al., 2011). In the context of the COSMOS project we used
the ACD/Labs Percepta software (ACD/Labs Percepta, release 2014.
Advanced Chemistry Development Inc., Toronto, Canada. www.
acdlabs.com) to predict several physico-chemical parameters (e.g.,
Log Kow, pKa, Fup) and ADME properties (e.g., passive oral
absorption, oral bioavailability, total body clearance) that were
used for the calibration of PBPK models.
4.2. From cells to tissues to whole body
As shown in the previous sections, not only the assessment of
concentrations in organelles, but also the assessment of cell
concentrations in a tissue is relevant to perform in vitro to in vivo
extrapolations (Martin et al., 2015). Since the liver as a whole is a
rather homogeneous organ, it is possible to represent it as an
average single cell containing relatively complex micro-organellesPlease cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026enveloping transport and molecular pathways (Krauss et al., 2012).
This approach balances the complexity of PBPK models and that of
molecular interactions, while reducing to a minimum the
complexity of the organ structure.
However, when the liver structure is analyzed in detail it
becomes clear that liver substructures are heterogeneous (Pang
and Rowland, 1977; Pang et al., 2007). In the liver tissue, blood is
distributed by portal veins into functional subunits, called lobules,
which carry out diverse functions including the detoxiﬁcation of
xenobiotics at the cellular level. The lobules capillaries distribute
blood and dissolved substances to various cells, and in particular
hepatocytes. In a lobule, blood transport produces a natural oxygen
gradient, introducing a zonation of the lobule, which in turn
induces a heterogeneous distribution of CYP expression factors in
the hepatocytes radially aligned in the lobule. The metabolism of
substances and the toxic response of the organ depend on this
heterogeneity.
That issue has attracted the attention of several groups and
projects (Holzhütter et al., 2012), and has motivated several
experimental initiatives, such as novel forms of cell cultures
(Soldatow et al., 2013). Mathematical models for the multi-scale
description of the liver have also been developed (Diaz Ochoa et al.,
2013; Hunt and Ropella, 2008; Pang et al., 2007; Wambaugh and
Shah, 2010).
Several publications have shown how such models can be
implemented to improve predictions of the in vivo toxic response
to small molecules. In our case (Diaz Ochoa et al., 2013), we
described the metabolism and detoxiﬁcation of acetaminophen in
the lobule using six sinusoids, which are capillary structures,
ordered to form a hexagonal shaped lobule. In each hepatocyte, a
metabolic network sub-model allows the estimation of the rate of
production of relevant metabolites and the production of oxidative
species. On this basis, we can estimate the clearance by the
simulated liver and apply it to the liver compartment in a PBPK
model. The explicit calculation of clearance using a parallel liver
model requires a concurrent parallelization. That opens a novel
computational way to integrate liver cells with an ever growing
molecular description complexity, depending on the information
available for the reconstruction of molecular pathways. This kind
of approach is essentially a “divide and conquer” strategy where
different sub-models are deﬁned in separate programs run in
parallel. Current developments are not restricted to the generation
of models or algorithms implemented in conventional machines.
For instance the use of cloud computing has also opened the
possibility to simulate very complex liver models with a high
degree of biological detail (Ropella and Hunt, 2010).
That approach allowed us to estimate local concentrations of
acetaminophen that potentially trigger cell necrosis, helping to
visualize liver damage after human exposure to a toxic dose of
acetaminophen (Fig. 5). Due to the coupling of the toxic response
and detoxiﬁcation it was possible to qualitatively estimate the
effect of the toxic response on the concentration of the substance
in the whole organism. Implementing cell dynamics and mechan-
ical cell interactions made it also feasible to visualize in detail liver
necrosis, closing the gap between in silico predictions and in vivo
outcomes (Drasdo et al., 2014).
However, for quantitative estimation, it is sometimes more
appropriate to directly couple the sub-cellular units to a PBPK
model. Simpler approaches combining PBPK modeling and
systems biology have investigated the coupling of a single complex
liver cell with internal metabolism (Bois, 2009; Péry et al., 2013).
Slightly more complex models describe the liver as a 1D tube
representing a liver sinusoid where the transport of substances is
coupled to the metabolism in the hepatocytes (Andersen et al.,
1997; Jones et al., 2012). Fig. 6 illustrates our implementation of
such a model.roaches for assessing cosmetic ingredients safety, Toxicology (2016),
Fig. 5. Visualization of liver damage at different times (in minutes) after the oral
application of acetaminophen for two virtual patients with different CYP expression
factors. The orange and black center area represents healthy and damaged liver
tissue, respectively. The six red ellipsoids at the periphery are the periportal veins
(reprinted from Diaz Ochoa et al., 2013; with permission).
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tages: they are less realistic because they assume that the
dispersion rate is homogeneous, implying that the substance
concentration is at equilibrium at any time in each compartment.
In general the lack of hydrodynamics, as well as the incorrect
representation of boundary conditions may hide some effects (like
differences in blood velocities within a sinusoid) related to the
transport of substances from the sinusoidal space to the
hepatocyte, as well as hinder the representation of the inherent
fractal structure of the organ (Dokoumetzidis and Macheras,
2003). However, the elimination of the explicit spatial dependence
allows a simple mathematical description using ordinary differ-
ential equations. This kind of less granular 1D-liver still captures
the essentials of the liver zonation and simultaneously increases
the calculation performance when cellular networks (metabolism
or cell regulation) are coupled to the hepatocyte. In summary, the
selection of the dimensionality of the liver model depends on the
level of complexity required for the quality of the in silico
predictions.
In Fig. 7 we present an example of the use of a zonated 1-D liver
for acetaminophen. In this example, an oral dose of 5 mg/kg wasFig. 6. 1D-liver model of the transport of a substance from portal veins to central veins 
deﬁned according to Table 1). In each hepatocyte the metabolism is described by a mo
phenotype along the sinusoid (zonation).
Please cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026assumed to be given to a man weighing 73 kg. The values of the
PBPK model parameters are based on those reported by Péry et al.
(2013). We assumed that primary metabolism in each hepatocyte
was adequately described by a Michaelis-Menten term, multiplied
by a scaling factor representing the differences in metabolic rate in
each zone of the liver. Without zonation this factor is equal 1 for all
hepatocytes. We ﬁrst compared the predictions of our model
without zonation to those obtained with a previously published
unstructured model (Péry et al., 2013).
We assumed a heterogeneous metabolism along the liver
sinusoid. Different signals like gradients of oxygen, nutrients,
metabolites, hormones and cytokines have an inﬂuence on
zonation since they modulate the activity of various enzymes
involved in the metabolic pathways (Gebhardt and Matz-Soja,
2014). However, the estimation of zonation factors is not trivial,
since they vary continuously in response to ﬂuctuating sinusoidal
patterns (Oinonen and Lindros, 1998). Glucuronidation is the
dominant pathway of conjugation at high APAP concentrations,
and is faster in the pericentral than in the periportal region, as has
been shown in experimental studies (Anundi et al., 1993).
Correspondingly, we selected a factor of 1.0 for the pericentral
zone, 0.5 for the midlobular zone, and 0.5 for the periportal zone
(Oinonen and Lindros, 1998). As a consequence, an overall increase
in acetaminophen concentrations and risk of toxic response was
observed (Fig. 7).
That model has been implemented as a KNIME work-ﬂow
(Berthold et al., 2007), increasing the portability of the model.
Based on this methodology, it is possible to write general PBPK
models that can easily be applied to different substances.
A signiﬁcant limitation is the difﬁculty to observe zonation in
vivo, limiting the possibility to validate the corresponding models.
Several advances in on-chip bioreactor technology mimicking a 1D
liver could help validate in silico models (Allen and Bhatia, 2003).
For example, advances in microﬂuidics have facilitated the
development of organs on-chip containing cells coupled to micro
vessels mimicking the capillaries of real organs (Dash et al., 2009;
Kimura et al., 2015), opening the possibility to directly observe
liver zonation and changes in metabolic rates. These advances
represent a potential method to deliver complementary results or
even couple in vitro and in silico methods to increase the
conﬁdence in both methods.in the sinusoid as well as its transport into the hepatocytes (parameters have been
lecular network. This enables the description of a heterogeneous metabolism and
roaches for assessing cosmetic ingredients safety, Toxicology (2016),
Table 1
Parameters required for the modeling of sinusoids in our 1D liver model (Fig. 6). All the parameters are scaled proportionally to the total liver volume.
Parameter Value or formula Source
Permeability (neutral substances) P = (log P  6.7) cm/s. Valid for neutral substances Trapp et al. (2008)
Transport through sinusoid 0.05 mm/s Vollmar and Menger (2009)
Mean sinusoid length 368 mm Grisham (2009)
Volume sinusoidal space 2.12  1013 L estimated by ourselves using hepatocyte volume
Volume Hepatocyte 5.09  1014 L Lodish (2000)
Sinusoid diameter 10 mm Grisham (2009)
Thickness of barrier between sinusoid and hepatocyte 2 mm Ostrovidov et al. (2004)
Approximated number of hepatocytes in the liver 109 Grisham (2009)
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double effect: they can improve the predictions made with such a
model, but they can also limit its use if new and unknown
parameters cannot be easily estimated (Poggesi et al., 2014).
Despite the difﬁculty of experimentally validating structured liver
models, they can be useful to study qualitatively the effect of
population variability in cytochromes expression on liver zonation,
to estimate risks involved in changes in zonation (induced for
example by other substances or liver damage), or to study the
impact of zonation on liver toxic response.Fig. 7. Model prediction of acetaminophen concentration-time proﬁles in three zones (1:
and in venous blood, with zonation of metabolism (red curves) or without zonation (blac
transport rate to hepatocytes was 1.40  101 L/min, and 1.08  102 L/min along the sinus
referred to the web version of this article.)
Please cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
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To predict safe levels of human exposure to general chemicals
we have so far usually relied on animal studies carried out mainly
by the oral route. However, for cosmetic ingredients the main route
of consumer exposure is expected to be dermal. For existing
chemicals, rather than carrying out additional animal studies using
a new exposure route (which goes against 3R principles and the
European Union ban on animal testing for cosmetics), route-to-
route extrapolation can be performed by modeling if reliable data periportal; 2: midlobular; 3: pericentral) of the liver sinusoid vessels or hepatocytes,
k curves), after a 5 mg/kg oral administration of acetaminophen of an adult man. The
oids. (For interpretation of the references to colour in this ﬁgure legend, the reader is
roaches for assessing cosmetic ingredients safety, Toxicology (2016),
Fig. 8. Concentration-time proﬁles of caffeine in blood after either bolus oral or
single application dermal exposure to an oral NOAEL dose (2.1 mg per kg of body
mass) (adapted from Gajewska et al., 2014).
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Henry, 1990). Obviously here, technical considerations as to the
type of in vitro assays to perform are essential. The mode of route-
to-route extrapolation should be decided on a case-by-case basis
(Nielsen et al., 2008). For example, the threshold of toxicological
concern (TTC) approach can eventually be applied (Worth et al.,
2012), and Kroes et al. (2007) give examples of how the TTC
approach can be applied to cosmetic ingredients and impurities.
They proposed that default factors should be used to adjust from an
external topical dose to an internal dose, followed by application of
the oral TTC values derived by Munro et al. (1996). PBPK modeling
provides a more mechanistic approach to route-to-route extrapo-
lation (Dourson and Felter, 1997; Reitz et al., 1988). In our recent
work on cosmetic ingredients, a series of PBPK models coupled to
VCBA models was developed to extrapolate between routes of
exposure for caffeine, coumarin, ethanol, hydroquinone, isopro-
panol and nicotine (Gajewska et al., 2014).Table 2
List of the biokinetics workﬂows developed in COSMOS and which are or will be avail
Type Chemical Exposure Spec
PBPK Caffeine Oral, dermal Hum
PBPK Coumarin Oral, dermal Hum
PBPK Ethanol Oral, inhalation Hum
PBPK Estragole Oral, dermal Hum
PBPK Hydroquinone Oral, dermal Hum
PBPK Isopropanol Oral, dermal Hum
PBPK Methyliodide Oral, dermal, inhalation Hum
PBPK Nicotine Intra-venous (IV) Hum
PBPK Styrene Inhalation Hum
PBPK Methotrexate Oral, dermal Hum
PBPK Valproic acid Oral, dermal Hum
PBPK Piperonyl butoxide Dermal Hum
PBPK General Oral, dermal, inhalation Hum
PBPK and bioaccumulation 90 chemicals
General
Oral
Oral
Hum
Hum
QIVIVE Caffeine Oral, dermal Hum
QIVIVE Coumarin Oral, dermal Hum
QIVIVE Estragole Oral, dermal Hum
QIVIVE General Oral, dermal Hum
VCBA 30 chemicals In vitro Hep
1D liver Coumarin Oral, inhalation, IV Hum
1D liver Caffeine Oral, inhalation, IV Hum
Please cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026We report here, as an example, the results for caffeine, based on
the use of a full PBPK model. Concentration-time proﬁles of
caffeine in blood, following either oral or dermal absorption were
simulated by our PBPK model at the oral NOAEL dose of 2.1 mg per
kg of body mass and per day (Fig. 8). These simulations were
performed for a male subject, weighing 75 kg. The concentration
versus time proﬁles for the two administration routes are clearly
different, which indicates that the NOAEL dose should probably not
be the same after oral or dermal exposures, as discussed in detail in
(Gajewska et al., 2014).
PBPK models can predict concentration-time proﬁles of a given
compound at the organ level or cell level (see above). In turn, the
predicted intracellular concentrations can be linked to cellular or
tissue level effect through the use of a concentration-effect
relationship (i.e., a model), such as the VCBA one or similar
(Gajewska et al., 2015; Paini et al., 2012), or more complex pathway
model (Hamon et al., 2014, 2015). Such a modeling approach has
the potential to predict effective target organ dose. Dose response
curves obtained based on in silico simulation and in vitro toxicity
data can be used to derive benchmark dose levels, usable as points
of departure for risk assessment. Acceptable human daily intake,
tolerable intakes, health based recommendation and exposure
limits can be set (Rietjens et al., 2011). In the speciﬁc case of a
cosmetic, the amount of an ingredient used in the ﬁnal formulation
can be restricted in order to obtain a ﬁnal product that does not
pose a health concern to the consumer.
5. From in silico models to automated workﬂows
Future human safety assessments are likely to rely strongly on
the use of multi-scale models, implemented through a combina-
tion of computational tools, in order to perform extrapolations
such as QIVIVE. The development of automated software tools is
now seen as an important step for harmonizing and expediting
chemical safety assessments. The KNIME workbench (Berthold
et al., 2007) provides a user-friendly graphical workﬂow interface
for data processing and analysis. Most of the mathematical models
developed within the framework of COSMOS – mostly written in R
(R Development Core Team, 2013) – have been implemented in the
KNIME platform. They already are or will soon be publicly available
through the COSMOS KNIME WebPortal (http://knimewebportal.
cosmostox.eu), with documentation and user guidance available atable in the COSMOS KNIME WebPortal at http://knimewebportal.cosmostox.eu.
ies Output
an, rat Time kinetics
an, rat Time kinetics
an, rat Time kinetics
an Time kinetics
an, rat Time kinetics
an, rat Time kinetics
an, rat Time kinetics
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an Time kinetics
an Time kinetics
an Time kinetics
an Time kinetics
an Time-dose kinetics
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an
Bio-accumulation factor
Bio-accumulation factor
an Time-dose kinetics
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an Time-dose kinetics
aRG, HepG2, 3t3balb/c, A549, cardiomyocytes Time-dose kinetics and effects
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Fig. 9. Schematic representation of a KNIME work-ﬂow developed for PBPK modeling for caffeine effects after oral and dermal exposure. The work ﬂow automatizes data
input, model parameters’ setting, simulation calls and output to different data streams. The core calculation are done in the “R snippet” nodes in the middle.
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capture of the KNIME caffeine work-ﬂow graphical interface.
Workﬂows offer a graphical interface for automatizing data input,
model parameters’ setting, simulation calls and output to different
data streams.
6. Conclusion
The work presented here was performed to develop a safety
assessment approach for cosmetic ingredients that does not rely on
the use of animal experiments and which is therefore compliant
with the European Union ban on animal testing. Two approaches
are available to maintain an acceptable safety level for those
products: The ﬁrst would be to use human based in vivo biomarker
assay. The second, and more realistic, is the combination of
predictive chemistry (in silico) assessments, based on legacy
knowledge from past animal experiments, in vitro testing, and
QIVIVE. We focused here on the latter. Mathematical or computer
modeling and in vitro experiments are complementary. A purely ab
initio chemistry-based approach is not currently feasible for
toxicity predictions, since the knowledge gap is too wide and has to
be ﬁlled with in vitro data. Such data by themselves are also
insufﬁcient. In vitro systems are still far from able to mimic a
human body and the data collected, essentially ﬁnite, need to be
interpolated and extrapolated in various ways. Modeling can help
there. We have made a modest contribution to the large
international endeavor in this ﬁeld, addressing various scales of
complexity: from the sub-cellular level (mitochondrial stress),
through the cellular one (cytotoxicity models), the tissue and organ
scale (liver), up to the whole body (with PBPK models).
The models we present are all relevant to the safety assessment
of cosmetic ingredients, but at various degrees, depending of the
depth of the assessment sought. Dermal exposure simulations are
available in all the PBPK models we developed. The KNIME
workﬂows for in vitro and in vivo kinetics’ simulations (Table 2) are
clearly the most readily applicable, in particular for QIVIVE in the
context of ab initio assessments (e.g., to predict in vivo cellular
levels which can be used in input to dose-response models
calibrated with in vitro data) (Hamon et al., 2015; Quignot et al.,
2014). We are actually using them in case studies demonstrating
the applications of the various tools developed in COSMOS andPlease cite this article in press as: F.Y. Bois, et al., Multiscale modelling app
http://dx.doi.org/10.1016/j.tox.2016.05.026other projects of the SEURAT cluster (the results will be reported
later in separate publications). The other models presented here
are more speciﬁc and have narrower scope. The liver model, for
example, should for now be reserved for in depth mechanistic
studies of particular chemicals and is too complex for high-
throughput screening. On the other hand, the models we
developed can be transposed to drugs or general chemicals
without problems.
One apparent issue in the overview we presented is the
deﬁnition of the boundaries between models. For example, where
should a PBPK model stop and where does systems biology
modeling start? The question may seem purely deﬁnitional, as we
know that a continuum exists from transport and metabolism to
metabolism control and signaling pathways, and that continuum
extends to cell–cell communications, to the tissue level etc.
However, it is also an operational question: What should
toxicologists, risk assessment practitioners and decision makers
expect from PBPK modeling? Certainly not an all-encompassing
tool. Our opinion is that PBPK models should focus on transport
and leave the details of metabolism and transport to systems
biology, so that the norm should be coupled PBPK – systems
biology – physiome models (Geenen et al., 2013; Hamon et al.,
2015). Or maybe PBPK models should rather be viewed as
particular (vascular system) physiome models? Not everyone
may agree with this view, as we tend to endorse the labels imposed
by customs and norms. Yet we should be open to changes,
particularly when they broaden our views and capabilities.
One limitation in this ﬁeld is our ability to deal with complex
computations based on massive data sets. This includes, for
example, the integration of omics data. Beyond multivariate
statistics, clustering and ad hoc approximate pathway analysis, the
integration of such data in a mechanistic framework is a scientiﬁc
and computational challenge (US EPA, 2014). Virtual tissues and
virtual body models are obviously extremely complex and few
research organizations have the capabilities to run them to a full
extent not to mention risk assessment practitioners, so that
simpliﬁed versions are still the norm. Computational and
mathematical methods still need improvement to meet this
challenge.
The modeling of adverse effects in humans is based on the fact
that toxicity pathways and mechanisms are in fact high-jackedroaches for assessing cosmetic ingredients safety, Toxicology (2016),
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TOX 51678 No. of Pages 10biological pathways, and toxic effects are a particular class of
physiological effects. While the use of modeling approaches and in
vitro methods to replace animal experiments remains a consider-
able challenge, advances in the ﬁeld are being made due to the
efforts of a very large community of scientists.
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